ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myositis"

  • Abstract Number: 2080 • ACR Convergence 2024

    HLA-DRB1*11:01 Association Differenciates Anti-hmgcr Immune-mediated Necrotizing Myopathy from Non-immune Mediated Statin Myotoxicity

    Cristina Corrales Selaya1, Diana Prieto-Peña2, gonzalo Ocejo-Viñals3, Carmen Secada Gómez4, alfonso Corrales-Martínez5, Carmen Ibarbia6, Zaida Salmón-gonzalez6, Marta Martín-millan6, Virginia Portilla-González6, Nerea mota-perez6, M. sebastian-mora gil6, J.C Batista-liz6, Veronica Pulito-Cueto7, Raquel Lopez-mejias7, Ricardo Blanco-Alonso8 and Jose Luis Hernandez6, 1Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 4Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 7IDIVAL, Santander, Spain, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Genetic risk factors may explain why only a small proportion of patients taking statins develop severe cases of anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune-mediated necrotizing myopathy…
  • Abstract Number: 0319 • ACR Convergence 2024

    Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis

    Farbod Moghaddam1, Mark Tarnopolsky2, Valérie Leclair3, marie Hudson3, Ross Mitchell4, Katherine Buhler1, Erin Hatcher5, Meifeng Zhang1, Antoine Dufour1, Luiz de Almeida1, Marvin Fritzler6 and May Choi1, 1University of Calgary, Calgary, AB, Canada, 2McMaster University, Hamilton, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Alberta, Edmonton, Canada, 5McMaster University, Hamilton, Canada, 6Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
  • Abstract Number: 0343 • ACR Convergence 2024

    An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies

    Georgina Harvey1, Idil Ashur2, Xavier Bossuyt3, Martin Bluethner4, Anna Brusch5, Chris Bundell5, hector Chinoy6, Claire Coeshott7, Charmaine Donald2, Juliet Dunphy8, Marvin Fritzler9, Adrian Heaps2, marie Hudson10, Masataka Kuwana11, Océane Landon-Cardinal12, Hui Lu1, FIONNUALA MCMORROW1, Marie Mayrhofer4, Alain Meyer13, Birthe Michiels3, Benoit Nespola14, Susan O'Loughlin15, Ivana Putova16, Johan Rönnelid17, Ross Sadler18, Maria Teresa Sanz-Martinez19, Paul Sciore20, Albert Selva-O’Callaghan21, Helena Storfors22, Ernesto Trallero-Araguás23, Yves Troyanov12, Jade Tyson2, Jiří Vencovský24, Akira Yoshida25 and Sarah Tansley1, 1University of Bath, Bath, United Kingdom, 2Severn Pathology, North Bristol NHS Trust, Bristol, United Kingdom, 3University Hospitals Leuven, Leuven, Belgium, 4MVZ Labor PD Dr. Volkmann und Kollegen GbR, Karlsruhe, Germany, 5Department of Clinical Immunology, PathWest Laboratory Medicine, Perth, Western Australia, Australia, 6The University of Manchester, Manchester, United Kingdom, 7Advanced Diagnostics Laboratories National Jewish Health, Denver, CO, 8Royal United Hospital Bath NHS Foundation Trust, Bath, United Kingdom, 9Mitogen Diagnostics Corp, Calgary, AB, Canada, 10McGill University, Montreal, QC, Canada, 11Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 12Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, 13UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, 14Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 15Greater Manchester Immunology Service, Manchester, England, United Kingdom, 16Institute of Rheumatology, Prague, Czech Republic, 17Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 18Laboratory of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom, 19Immunology Division, Vall d'Hebron Hospital, Barcelona, Spain, 20Mitogen Diagnostics Corp., Calgary, 21Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, 22Department of Clinical Immunology and Transfusion Medicine, Uppsala University Hospital, Uppsala, Sweden, 23Rheumatology Departament, Vall d'Hebron Hospital, Barcelona, Spain, 24Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 25Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

    Background/Purpose: In idiopathic inflammatory myopathy (IIM) spectrum diseases, myositis-specific and myositis-associated autoantibodies (MSAs/MAAs) are key markers of disease subtype and prognosis and are considered routine…
  • Abstract Number: 1149 • ACR Convergence 2024

    Cause-Specific Proportionate Mortality Trends in Idiopathic Inflammatory Myopathies

    Ansaam Daoud1, Muhammad Shamim2, Loai Dweik3 and Haseeb Chaudhary4, 1Case Western Reserve University/University Hospitals, Akron, OH, 2University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 3Cleveland Clinic Akron General Internal Medicine, Akron, OH, 4Case Western Reserve University, Westlake, OH

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are associated with increased morbidity, mortality, and economic health burden compared to the general population despite advancements in overall disease management.…
  • Abstract Number: 1168 • ACR Convergence 2024

    Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan

    Masataka Kuwana1, Kenichi Masui2, Atsushi Kawakami3, Takafumi Suda4, Shinji Sato5, Yasushi Kawaguchi6, Takeshi Johkoh7, Tomoaki Hoshino8, Naoki Shimada9, Yasuhiro Kondoh10, Yoshinori Tanino11, Tohru Takeuchi12, Yoshiyuki Abe13, Naoki Kimura14, Yasushi Inoue15, Keisuke Tomii16, Toru Arai17, Kunihiro Yamaoka18, Kaneshige Sasaki19, Taio Naniwa20, Ran Nakashima21, Kenjiro Shima22, Osamu Nishiyama23, Yuko Waseda24, Hiroshi Mukae25, Hirofumi Chiba26, Keigo Ikeda27, Kazuya Ichikado28, Yohei Kirino2, Koichi Amano29, Takashi Nawata30, Tomoo Kishaba31, Daisuke Asatori32, Daisuke Kobayashi22 and Takahisa Gono33, 1Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 2Yokohama City University School of Medicine, Yokohama, Japan, 3Nagasaki University, Nagasaki, Japan, 4Hamamatsu University School of Medicine, Hamamatsu, Japan, 5Tokai University School of Medicine, Isehara, Japan, 6Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 7Kansai Rosai Hospital, Amagasaki, Japan, 8Kurume University School of Medicine, Kurume, Japan, 9International University of Health and Welfare, Ohtawara, Japan, 10Tosei General Hospital, Seto, Japan, 11Fukushima Medical University School of Medicine, Fukushima, Japan, 12Osaka Medical and Pharmaceutical University, Takatsuki, Japan, 13Juntendo University School of Medicine, Tokyo, Japan, 14Tokyo Medical and Dental University, Tokyo, Japan, 15Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, 16Kobe City Medical Center General Hospital, Kobe, Japan, 17NHO Kinki Chuo Chest Medical Center, Sakai, Japan, 18Kitasato University School of Medicine, Sagamihara, Japan, 19Kainan Hospital, Yatomi, Japan, 20Nagoya City University, Nagoya, Japan, 21Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 22Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 23Kindai University Faculty of Medicine, Osakasayama, Japan, 24University of Fukui, Eiheiji, Japan, 25Nagasaki University Hospital, Nagasaki, Japan, 26Sapporo Medical University, Sapporo, Japan, 27Juntendo University Urayasu Hospital, Urayasu, Japan, 28Saiseikai Kumamoto Hospital, Kumamoto, Japan, 29Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan, 30Yamaguchi University Graduate School of Medicine, Ube, Japan, 31Okinawa Chubu Hospital, Uruma, Japan, 32Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, 33Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: ILD is the leading cause of mortality in patients with idiopathic inflammatory myopathies, and rapidly progressive ILD, associated mainly with anti-MDA5 antibody, is the…
  • Abstract Number: 1779 • ACR Convergence 2024

    Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers

    Jessica Turnier1, Chioma Madubata2, Christine Goudsmit3, Sean Ferris3, Celine Berthier3, Zilan Zheng4, Sophia Matossian3, Jeff Dvergsten5, Meredyth Wilkinson6, Lucy R Wedderburn7, Gabrielle Morgan8, Lauren Pachman9, Claudia Lalancette3, Stephen Parker3, Andrew Heaton10, J. Michelle Kahlenberg3, Gabriela K Fragiadakis2 and Jessica Neely4, 1University of Michigan, Saline, MI, 2University of California, San Francisco, San Francisco, CA, 3University of Michigan, Ann Arbor, MI, 4UCSF, San Francisco, CA, 5Duke University Hospital, Hillsborough, NC, 6Great Ormond Street Institute of Child Health, London, United Kingdom, 7UCL GOS Institute of Child Health, London, United Kingdom, 8Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 9Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 10Cure JM, Leesburg, VA

    Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children, and it frequently follows a chronic disease course. Treatments are limited secondary…
  • Abstract Number: 2082 • ACR Convergence 2024

    Different Clinical Phenotypes of Patients with Anti-synthetase Syndrome: Unsupervised Cluster Analysis in the CLASS Database

    Akira Yoshida1, Iazsmin Bauer Ventura2, Eduardo Dourado3, Giovanni Zanframundo4, Sara Faghihi Kashani5, Aravinthan Loganathan6, Daphne Rivero Gallegos7, Francisca Bozan8, Gianluca sambataro9, Sangmee Bae10, Ernesto Trallero-Araguás11, Andrew Mammen12, Carlo Scire13, Carlomaurizio Montecucco14, Chester Oddis15, David Fiorentino16, Francesco Bonella17, Frederick Miller18, Antonella Notarnicola19, Jens Schmidt20, Jorge Rojas-Serrano21, marie Hudson22, Masataka Kuwana23, Miguel Angel Gonzalez-Gay24, Neil McHugh25, Tamera J Corte26, Tracy J Doyle27, Victoria Werth28, Rohit Aggarwal29 and Lorenzo Cavagna30, and the CLASS project investigators, 1Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 2University of Chicago, Chicago, IL, 3Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, 4Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, 5UCSF, Mountain View, CA, 6RUH, Middle Park, Queensland, Australia, 7INER, Ciudad de México, Mexico State, Mexico, 8Hospital Clinico Universidad de Chile, Santiago, Chile, 9University of Catania, Catania, Italy, 10UCLA, Los Angeles, CA, 11Rheumatology Departament, Vall d'Hebron Hospital, Barcelona, Spain, 12NIH, Bethesda, MD, 13University of Milano Bicocca, Milan, Italy, 14IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 15Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 16Stanford University, Menlo Park, CA, 17Center for Interstitial and Rare Lung Disease Unit, University of Duisburg-Essen, Ruhrlandklinik, Essen, Germany, Essen, Germany, 18NIH, NIEHS, Chapel Hill, NC, 19Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 20University Medical Center Goettingen, Göttingen, Germany, 21National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, 22McGill University, Montreal, QC, Canada, 23Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 24University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 25University of Bath, Bath, United Kingdom, 26Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, 27Brigham and Women's Hospital, West Roxbury, MA, 28University of Pennsylvania, Wynnewood, PA, 29Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 30University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy

    Background/Purpose: Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease with significant heterogeneity. The Classification Criteria for Anti-Synthetase Syndrome (CLASS) project is an international…
  • Abstract Number: 0320 • ACR Convergence 2024

    Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis

    Iago Pinal-Fernandez1, Daniel Reay2, Timothy Oriss2, katherine Pak3, Maria Casal-Dominguez4, jose milisenda5, Albert Selva-O’Callaghan6, Werner Stenzel7, Andrew Mammen1 and Dana Ascherman8, 1NIH, Bethesda, MD, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, 3National Institutes of Health, Bethesda, MD, 4NIH, Bathesda, MD, 5Hospital Clinic de Barcelona, Barcelona, Spain, 6Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, 7Charite University, Berlin, Germany, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

    Background/Purpose: Previous work has shown unique gene expression profiles in muscle tissue corresponding to the anti-synthetase syndrome, with an emphasis on interferon gene signatures (Type…
  • Abstract Number: 0344 • ACR Convergence 2024

    Characteristics of Patients with Antisynthetase Antibodies

    Danny Kasto1, Michael McLucas2, Anne-Marie Aubin2, Armando Faigl2 and Gabor Major1, 1Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, New South Wales, Australia, 2Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, Australia

    Background/Purpose: Aminoacyl transfer RNA synthetase antibodies (ASAbs) are associated with a range of clinical manifestations, including severe lung and muscle disease and are postulated to…
  • Abstract Number: 1150 • ACR Convergence 2024

    Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies

    Sylvia Raftopoulou1, Nikolaos Michalakeas1, Maria Gerochristou2, Nikolaos Marketos1, Charalampos Skarlis1 and Clio Mavragani3, 1Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, 2Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, 3Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterised by muscle inflammation (myositis) and weakness, impacting various organ systems. Clinical subtypes include dermatomyositis (DM), antisynthetase syndrome (ASyS),…
  • Abstract Number: 1170 • ACR Convergence 2024

    Computer Aided Lung Informatics, HRCT and PFT in Patients with Interstitial Lung Disease in Idiopathic Inflammatory Myopathies

    Sonali Narain1, Kourosh Shargani2, Ivana Ilic3, Irvind Buttar4 and Galina Marder5, 1Northwell Health, Great Neck, NY, 2Northwell, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Northwell Health/ Lenox Hill Hospital, Dix Hills, NY, 5Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Evaluation of Interstitial Lung Disease (ILD) progression relies on high resolution computed tomography (HRCT) and pulmonary function test (PFT). As we previously reported in our Idiopathic…
  • Abstract Number: 2060 • ACR Convergence 2024

    Clustering Analysis of Immune Cell Subtypes and Clinical Phenotypes in Idiopathic Inflammatory Myopathy

    xiaoyan xing1, Yuhui Li2 and Jing He3, 1Department of Rheumatology and Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China, Beijing, China, 2Peking University, BeiJing, China, 3Rheumatology, Beijing, China

    Background/Purpose: Immune cell profiling plays a pivotal role in the pathogenesis of idiopathic inflammatory myopathy (IIM). Characterizing immune cell subtypes, such as CD4+ T cells,…
  • Abstract Number: 2083 • ACR Convergence 2024

    A Novel Scoring System to Predict a Cancer Development in Patients with Idiopathic Inflammatory Myopathy

    Yun Kyu Kim1, Ju yeon Kim2, Jung Yoon Pyo3, Min Jung Kim4, Jin Kyun Park5, Eun Young Lee6, Yun Jong lee3, eun Bong Lee1 and Jun Won park2, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 3Seoul National University Bundang Hospital, Seongnam-si, 4Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, 5Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, 63Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Previous studies have demonstrated that idiopathic inflammatory myopathy (IIM) is associated with an elevated cancer risk. However, there is limited evidence on the specific…
  • Abstract Number: 0321 • ACR Convergence 2024

    Diffusion Weighted Imaging in Muscle MRI Can Detect Quantitative Improvements in Muscle Edema: A Post-hoc Analyses of the Study of Tofacitinib in Refractory Dermatomyositis

    Julie Paik1, Patrick Debs2, Anshula Nallapati1, Lisa Christopher-Stine1, Jemima Albayda3, Eleni Tiniakou4 and Laura Fayad2, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins Radiology, Baltimore, MD, 3Johns Hopkins School of Medicine, Baltimore, MD, 4Johns Hopkins University, Lutherville Timonium, MD

    Background/Purpose: Diffusion weighted imaging (DWI) in muscle magnetic resonance imaging is an underutilized, quantitative assessment tool in idiopathic inflammatory myopathies (IIM). It is not uncommon…
  • Abstract Number: 0346 • ACR Convergence 2024

    Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls

    Amelia Sawyers1, Leslie Crofford2, Erin Wilfong3 and Rachel Bonami3, 1Vanderbilt University School of Medicine, Nashville, TN, 2Vanderbilt University Medical Center, Melbourne, AR, 3Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a collection of rare, systemic rheumatic diseases. A role for B cells in IIM is indicated by the success…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology